424870 — ImmuneOncia therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- KR₩361bn
- KR₩361bn
- KR₩655m
Annual cashflow statement for ImmuneOncia therapeutics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Net Income/Starting Line | 8,864 | -5,687 |
| Depreciation | ||
| Amortisation | ||
| Non-Cash Items | -18,909 | -5,622 |
| Unusual Items | ||
| Other Non-Cash Items | ||
| Changes in Working Capital | 677 | -4,406 |
| Change in Accounts Receivable | ||
| Change in Prepaid Expenses | ||
| Change in Other Assets | ||
| Change in Accounts Payable | ||
| Change in Accrued Expenses | ||
| Change in Taxes Payable | ||
| Change in Other Liabilities | ||
| Other Operating Cash Flow | ||
| Cash from Operating Activities | -8,337 | -14,663 |
| Capital Expenditures | -428 | -139 |
| Purchase of Fixed Assets | ||
| Purchase / Acquisition of Intangibles | ||
| Other Investing Cash Flow Items | -4,903 | 1,867 |
| Sale/Maturity of Investment | ||
| Purchase of Investments | ||
| Other Investing Cash Flow | ||
| Cash from Investing Activities | -5,332 | 1,728 |
| Financing Cash Flow Items | — | -3.18 |
| Other Financing Cash Flow | ||
| Net Issuance / Retirement of Stock | ||
| Net Issuance / Retirement of Debt | ||
| Cash from Financing Activities | 7,896 | 200 |
| Foreign Exchange Effects | ||
| Beginning Cash Balance | ||
| Ending Cash Balance | ||
| Net Change in Cash | -5,773 | -12,731 |